Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
manhattan hotel
Popular Articles
Cellulite Cream

Policymakers, Experts, Public Agree: Physical Activity Plan Needed
Dozens of the nation"s leading organizations in health care, science, medicine and public health are meeting in Washington, D.C., this week with one goal in mind: to develop a national physical activity plan that will make America healthier. Congressional leaders and members of the public both agree that emphasizing disease prevention measures, such as increasing physical activity, is essential to combating chronic diseases, which account for 70 percent of all deaths in the U.S., according to the Centers for Disease Control and Prevention.
generic viagra online
Healthier, Longer-Lasting Fish Filets With Edible Coating
Consumers may be able to eat longer-lasting, potentially healthier fish fillets if research at Oregon State University makes its way to the supermarket.
News of the day
New Center Of Excellence Targets Reducing Disparities In Cancer Care And Outcomes
The University of South Florida and Moffitt Cancer Center have been awarded a highly competitive, $6-million federal grant to create a National Center on Minority Health and Health Disparities (NCMHD) Center of Excellence. The five-year program grant from the NCMHD, National Institutes of Health, will focus on research, education and training, and community outreach activities to reduce cancer-related health disparities among minority and underserved communities in Florida.
Public Health

Oculus Innovative Sciences Receives FDA Clearance For Microcyn(R) Skin And Wound Gel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Microcyn® Skin and Wound Gel as both a prescription and over-the-counter formulation. The Rx product, under the supervision of a health care professional, is intended for management of exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically debrided wounds. This is the first hydrogel product based upon the Microcyn Technology platform and is reimbursable by both Medicare and Medicaid. The original Microcyn-based solution, branded as Microcyn Wound Care in the United States, Microdacyn60™ in Mexico, Dermacyn™ Wound Care in Europe and China and Oxum in India, has treated over one million patients worldwide without a report of a single serious adverse effect. "We are pleased to receive FDA clearance for this Microcyn hydrogel product," said Hoji Alimi, founder and CEO of Oculus. "We understand the critical role that reimbursement plays in the successful commercialization of a medical product, and in that this is our first reimbursable product, we plan to aggressively market to the U.S. healthcare community. At the same time, we are taking all steps necessary to secure regulatory approvals outside North America so as to begin generating international sales through our existing distribution channels worldwide." Oculus Innovative Sciences, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009